slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 71,311-71,340
Pages 3,679
Rows per page 30
Component
71,311-71,340 of 110,355
02
Absci | Investor Presentation Deck | 48 slidesAbsci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations 1 hit
07
The slide uses a metaphor to frame the company's value proposition against the backdrop of low clinical trial success rates.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
13
The slide uses a 5-step process flow diagram to explain the technical methodology.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
16
The heatmap shows edit distance between pairs of HCDR3 sequences; the table shows specific examples of designed sequences and their binding affinity (-Log10 Kd).Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
22
The slide uses a visual comparison between a small sampled space (50k) and a massive hypothetical space (7x10^6) to illustrate the efficiency of the AI approach.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
25
The slide uses two line charts to show optimization over generations and a scatter plot to show the distribution of variants.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
26
The slide uses a histogram to visualize the distribution of binding affinity (-log10(KD)) for designed variants compared to the wild-type Trastuzumab baseline.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
30
Includes a biological diagram of TLS and a Kaplan-Meier survival curve.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
32
The slide highlights the scale of the antibody discovery pipeline and the distribution of therapeutic focus areas.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
38
The slide uses a bar chart to show that even with 3 nsAA sites, the relative expression remains comparable to wild-type, validating the platform's efficiency.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
44
Uses authority-citation to build credibility.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
47
The slide uses a growth curve to illustrate technological progression over time.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
06
The slide uses a donut chart to compare 2021 and 2028 market sizes, highlighting growth.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Golden Circle1 hit
07
Aeglea BioTherapeutics | Investor Presentation Deck | 56 slidesAeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Golden Circle1 hit
08
The chart uses a visual metaphor of a 'ceiling' (the 40% remission line) and an arrow to indicate the desired shift in therapeutic performance.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Golden Circle1 hit
11
The slide uses a 'before-after' logic to justify the combination strategy.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Golden Circle1 hit
16
The chart uses a dual-axis approach to imply a safety-efficacy trade-off, positioning vedolizumab as the 'safest' and highly effective.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
20
The slide demonstrates bio-equivalence in binding affinity to a specific T-cell population.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
21
The chart compares SPY001 against two vedolizumab datasets (internal and Takeda).Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
26
Includes production capacity metrics and automation statistics.VinFast | Investor Presentation Deck | 42 slides · VinFast
Pitch deck Investor relations 1 hit
28
The chart uses a stacked bar format to compare depreciation and out-of-pocket expenses.VinFast | Investor Presentation Deck | 42 slides · VinFast
Pitch deck Investor relations 1 hit
29
Uses a stacked bar chart for segment growth and a concentric circle diagram for TAM expansion.VinFast | Investor Presentation Deck | 42 slides · VinFast
Pitch deck Investor relations Beat · Market Size1 hit
30
The slide uses a stacked bar chart for market share, a bubble/dot chart for growth rates, and a horizontal bar chart for penetration.VinFast | Investor Presentation Deck | 42 slides · VinFast
Pitch deck Investor relations Beat · Market Size1 hit
07
The slide emphasizes the multi-device (desktop/mobile) nature of the product and its role as a central hub for seller operations.Vivid Seats | Investor Presentation Deck | 24 slides · Vivid Seats
Pitch deck Investor relations Beat · Solution1 hit
12
The slide uses a bubble/Venn-style diagram to show market scope and a bar chart for TAM growth.Vivid Seats | Investor Presentation Deck | 24 slides · Vivid Seats
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
15
The slide uses dashed boxes to visually isolate the COVID-19 impacted period (FY 2020-2021).Vivid Seats | Investor Presentation Deck | 24 slides · Vivid Seats
Pitch deck Investor relations Beat · FinancialsLoop · Quick Win Big Bet1 hit
16
2020 data is omitted due to COVID-19.Vivid Seats | Investor Presentation Deck | 24 slides · Vivid Seats
Pitch deck Investor relations Beat · FinancialsLoop · Quick Win Big Bet1 hit
17
The slide uses a dual-chart layout to contrast GAAP vs non-GAAP performance metrics.Vivid Seats | Investor Presentation Deck | 24 slides · Vivid Seats
Pitch deck Investor relations Beat · Financials1 hit
19
Uses a hub-and-spoke diagram to illustrate components of strategic flexibility.Vivid Seats | Investor Presentation Deck | 24 slides · Vivid Seats
Pitch deck Investor relations Beat · Financials1 hit
22
The slide uses a dashed box to visually isolate the COVID-19 impacted period (FY 2020-2021).Vivid Seats | Investor Presentation Deck | 24 slides · Vivid Seats
Pitch deck Investor relations 1 hit